Wedbush reaffirmed their outperform rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research note released on Wednesday morning. The brokerage currently has a $37.00 target price on the stock. Wedbush also issued estimates for Allena Pharmaceuticals’ Q1 2018 earnings at ($0.38) EPS, Q2 2018 earnings at ($0.38) EPS, FY2018 earnings at ($1.50) EPS, FY2019 earnings at ($1.91) EPS, FY2020 earnings at ($2.12) EPS and FY2021 earnings at ($2.61) EPS.
Several other research analysts have also recently weighed in on ALNA. ValuEngine raised shares of Allena Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 2nd. Zacks Investment Research cut Allena Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Allena Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $26.67.
Allena Pharmaceuticals stock opened at $11.02 on Wednesday. The firm has a market capitalization of $228.07 and a PE ratio of -2.30. Allena Pharmaceuticals has a fifty-two week low of $6.13 and a fifty-two week high of $15.40. The company has a current ratio of 12.74, a quick ratio of 4.83 and a debt-to-equity ratio of 0.07.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNA. Frazier Management LLC bought a new position in Allena Pharmaceuticals in the fourth quarter valued at $33,504,000. Sphera Funds Management LTD. bought a new position in Allena Pharmaceuticals in the fourth quarter valued at $3,270,000. Perceptive Advisors LLC bought a new position in Allena Pharmaceuticals in the fourth quarter valued at $2,515,000. BlackRock Inc. bought a new position in Allena Pharmaceuticals in the fourth quarter valued at $2,281,000. Finally, Goldman Sachs Group Inc. bought a new position in Allena Pharmaceuticals in the fourth quarter valued at $499,000. 84.21% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/03/31/allena-pharmaceuticals-alna-earns-outperform-rating-from-wedbush.html.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.